Biotech News

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

IRIDEX (IRIX)IRIDEX2026-04-07 20:05 ESTPartnership

MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership

Related news

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

OCGNOcugen2026-07-13 11:02 EST

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

RXSTRxSight2026-07-06 20:16 EST

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

BLTEBelite Bio2026-06-13 01:30 EST

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

View all latest news

IRIDEX

IRIDEX is a medical device company focused on ophthalmic laser systems and eye-care procedures. Its business is built around retina and glaucoma treatment platforms.

Recent company news

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

IRIXIRIDEX2026-05-19 20:05 EST

Iridex Reports First Quarter 2026 Financial Results

IRIXIRIDEX2026-05-05 20:05 EST

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

Stock data

Close: 0.84 USD
Market cap: 20.37M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States